uniQure N.V. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019; filed March 2, 2020. The filing also provides unaudited fourth-quarter results. Amounts are in U.S. dollars unless stated otherwise.
Business context
uniQure is a clinical-stage gene-therapy company developing AAV-based treatments for rare and serious diseases. Its lead program, etranacogene dezaparvovec (AMT-061) for hemophilia B, was in a Phase III pivotal trial; AMT-130 for Huntington’s disease entered Phase I/II patient screening. AMT-180 (hemophilia A), AMT-190 (Fabry disease) and AMT-150 (SCA3) remained preclinical. The company has not generated significant product-sale revenue and reported no approved commercial products.
Financial performance and position
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $7.3 million | $11.3 million |
| Research and development expense | $94.7 million | $74.8 million |
| Selling, general and administrative expense | $33.5 million | $25.3 million |
| Operating loss | $121.1 million | $88.2 million |
| Net loss | $124.2 million | $83.3 million |
| Net loss per share | $3.11 | $2.34 |
| Cash, cash equivalents and restricted cash at year-end | $380.7 million | $237.3 million |
| Total debt at year-end | $36.1 million | $35.5 million |
Revenue consisted of BMS license revenue ($5.0 million) and collaboration revenue ($2.3 million). The company reported no product sales. Gross margin is not presented as a meaningful measure for this development-stage business.
Operating cash use was $98.7 million, compared with $76.0 million in 2018; investing cash use was $6.6 million. Financing generated $248.8 million, principally from the September 2019 share offering. Current assets were $384.2 million and current liabilities $31.6 million; cash and cash equivalents alone were $377.8 million. The company said available cash was expected to fund operations and capital needs into mid-2022.
Debt included $35.0 million principal under the Hercules facility, bearing interest at 8.85% at year-end. Principal repayment was scheduled to begin in January 2022, with facility maturity in June 2023. Operating lease liabilities were $37.0 million; total undiscounted operating lease payments were $62.2 million.
Changes versus prior comparable periods
- Annual revenue declined about 35% from 2018, primarily as BMS license and collaboration revenue decreased; BMS remained the source of all 2019 revenue.
- Net loss widened by $40.9 million. R&D expense increased $19.9 million, reflecting clinical and preclinical development, while SG&A rose $8.2 million.
- Operating cash use increased by $22.6 million. The September offering provided $242.7 million in net proceeds and materially increased year-end cash.
- Fourth-quarter 2019 revenue was $2.6 million and net loss was $41.4 million, compared with $1.6 million and $21.9 million, respectively, in fourth-quarter 2018.
Outlook, commentary and notable risks
- Management expected operating losses to increase as it advances clinical programs, expands research and manufacturing capabilities, prepares for potential commercialization, and invests in regulatory and commercial infrastructure. The company did not provide revenue or earnings guidance; it stated it did not expect revenue before 2022.
- HOPE-B had enrolled approximately 60 patients in its six-month lead-in phase. In a separate three-patient Phase IIb study, mean FIX activity was 41% of normal at 52 weeks; the small sample and limited follow-up do not establish pivotal-trial outcomes.
- The BMS collaboration’s initial research term ended in May 2019. Discussions to restructure or amend the arrangements were ongoing, with potential changes to obligations, economics, manufacturing responsibilities and BMS warrants; no outcome was assured.
- After year-end, Pfizer filed a petition seeking inter partes review of claims in a uniQure U.S. patent covering FIX-Padua. The filing also disclosed oppositions to a European FIX patent and an appeal of a refused divisional application.
- Key risks include clinical and regulatory failure or delay, long-term gene-therapy safety and durability, manufacturing and scale-up challenges, competition, intellectual-property challenges, uncertain reimbursement and pricing, and dependence on additional capital. Management highlighted potential COVID-19 effects on clinical sites and operations as a risk.
- Future milestone and royalty obligations to licensors may arise upon specified development, regulatory or commercial events; their amounts and timing were not reliably estimable. No legal proceedings were reported. The company reported effective disclosure controls and internal control over financial reporting; the 2019 financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Subsequent HOPE-B results, including FIX activity, bleeding rates, safety, follow-up duration and regulatory milestones.
- AMT-130 trial enrollment, safety and progress, and the timing and cost of advancing other preclinical programs.
- Cash burn and runway relative to management’s mid-2022 estimate, including the effect of trial, manufacturing and commercialization spending.
- Any BMS agreement amendments, continuing reimbursements, future economic rights and potential warrant-related dilution.
- Outcomes of the Pfizer patent review petition and European patent oppositions or appeals, and the resulting effect on protection for etranacogene dezaparvovec.
- Debt repayment terms, lease commitments, and any financing needs or changes in access to capital.